Page 237 - 2020_07-Haematologica-web

High uric acid levels and increased mortality after alloSCT
Table 1. Patient characteristics.
Year of transplant median (range)[IQR]
Patient age (years) median(range) Time from diagnosis to transplant (months) median (range)
Sex mismatch
Female to male Other combination Missing
Diagnosis
Acute leukemia Lymphoma MDS
Disease status
CR
Not in CR Missing
Uric acid ≤4.3 mg/dL (n=186) 2015 (2014-2018) [2015-2017]
52 (17-71) 4 (1-61)
30 (17%) 148 (83%) 8
130 (70%) 17 (9%) 39 (21%)
120 (66%) 61 (34%) 5
Uric acid >4.3 mg/dL (n=180) P 2015 (2014-2018) [2014-2016] 0.10
55 (20-71) 0.11 5 (1-71) 0.09
52 (29%) 0.005 125 (71%)
3
118 (66%) 0.7 19 (10%)
43 (24%)
125 (72%) 0.2 48 (28%)
DRI
Low 8(4%) 7(4%) Intermediate 107 ( 60% ) 105 ( 63% ) High 51(30%) 49(30%) Veryhigh 10(6%) 5(3%)
0.7
Missing
ATG
No
Yes
Conditioning intensity
MAC/Chemo MAC/TBI RIC
Missing
GvHD prophylaxis
Calcineurin inhibitor + MMF Calcineurin inhibitor + MTX Calcineurin inhibitor mono Missing
Donor/patient CMV -/-
Other
Missing
Karnofsky score
10-80 90-100 Missing
HT-CI=0 HT-CI=1or2 HT-CI≥3 Missing
10
100 (54%)
86 (46%)
46 (25%) 36 (20%) 102 (55%) 2
85 (48%) 64 (36%) 27 (15%) 10
28 (16%) 146 (83%) 12
38 (21%) 140 (78%) 8 64(50%) 20(15%) 45(35%) 57
14
7
106 (59%) 0.3
74 (41%)
37 (21%) 0.2 26 (15%)
115 (64%) 2
84 (47%) 0.6 71 (40%)
22 (12%)
3
38 (21%) 136 (78%) 6
27 (15%) 149 (84%) 4
0.2
0.14
56(40%) 0.19 32(23%)
51(37%)
41
MDS: myelodysplastic syndrome; IQR: interquartile range; CR: complete remission; DRI: disease risk index; ATG: anti-thymocyte globulin; MAC: myeloablative conditioning; RIC: reduced intensity conditioning; TBI: total body irradiation; GvHD: graft-versus-host disease; MMF: Mycophenolate mofetil; MTX: Methotrexate; CMV: cytomegalovirus; HT-CI: hematopoietic cell transplantation cumulative incidence.
haematologica | 2020; 105(7)
1979